• 1
    Hasse B, Ledergerber B, Furrer H et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53: 11301139.
  • 2
    Cockerham L, Scherzer R, Zolopa A et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr 2010; 53: 102106.
  • 3
    Zwahlen M, Harris R, May M et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38: 16241633.
  • 4
    Guaraldi G, Orlando G, Zona S et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53: 11201126.
  • 5
    Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 25062512.
  • 6
    Goulet JL, Fultz SL, Rimland D et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007; 45: 15931601.
  • 7
    Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471477.
  • 8
    Currier JS, Taylor A, Boyd F et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506512.
  • 9
    Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 19932003.
  • 10
    Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 17231735.
  • 11
    Friis-Moller N, Thiebaut R, Reiss P et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17: 491501.
  • 12
    Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121 (1 Pt 2): 293298.
  • 13
    Wilson PW, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 18371847.
  • 14
    D'Agostino RB Sr, Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743753.
  • 15
    Ferrario M, Chiodini P, Chambless LE et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol 2005; 34: 413421.
  • 16
    Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007; 93: 172176.
  • 17
    Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310315.
  • 18
    Hippisley-Cox J, Coupland C, Vinogradova Y et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 335: 136.
  • 19
    D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180187.
  • 20
    Lang S, Mary-Krause M, Cotte L et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24: 12281230.
  • 21
    Schouten J, Wit FW, Stolte IG et al. Comorbidity and ageing in HIV-infection: the AGEhIV Cohort Study. XIX International AIDS Conference. Washington, DC, July 2012 [Abstract THAB0205].
  • 22
    Glass TR, Ungsedhapand C, Wolbers M et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med 2006; 7: 404410.
  • 23
    Santos J, Palacios R, Gonzalez M, Ruiz J, Marquez M. Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Netar Study). Int J STD AIDS 2005; 16: 677680.
  • 24
    Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 11791193.
  • 25
    Smith CJ, Levy I, Sabin CA et al. Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. HIV Med 2004; 5: 8892.
  • 26
    Grierson J, Thorpe R, Saunders M, Pitts M. HIV Futures4: State of the [Positive] Nation, Monograph Series Number 48. Melbourne, Vic., The Australian Reseach Centre in Sex, Health and Society, Latrobe University, 2004.
  • 27
    Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav 2010; 14: 824835.
  • 28
    Iloeje UH, Yuan Y, L'Italien G et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6: 3744.
  • 29
    Petoumenos K, Worm S, Reiss P et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). HIV Med 2011; 12: 412421.